<DOC>
	<DOCNO>NCT00394654</DOCNO>
	<brief_summary>This Phase 2a , randomize multicenter study evaluate efficacy MEDI-528 LAR adult patient atopic asthma .</brief_summary>
	<brief_title>A Study Evaluate Efficacy MEDI-528 Late Asthmatic Response With Atopic Asthma</brief_title>
	<detailed_description>This study ( MI-CP138 ) Phase 2a , randomize , double-blind , placebo-controlled , multicenter study evaluate efficacy MEDI-528 LAR adult patient atopic asthma . Approximately three investigative site Canada participate study , 40 evaluable patient randomize 1:1 ratio receive MEDI-528 ( 9.0 mg/kg ) placebo single IV infusion .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female adult , age 18 65 year age time screen ; Written inform consent obtain patient prior receipt study medication begin study procedure ; Previously document diagnosis asthma &gt; 1 year duration , base episodic symptom airflow obstruction , least partial reversibility airflow obstruction , alternative diagnosis ( e.g. , chronic obstructive pulmonary disease ) rule ; AHR methacholine challenge test PC20 ( provoke concentration methacholine cause 20 % fall FEV1 ) ≤ 16 mg/mL ( Crapo , 2000 ) ; Have dual response EAR , define decrease FEV1 ≥ 20 % 0 3 hour inhalation , LAR , define decrease FEV1 ≥ 15 % 3 7 hour inhalation , inhaled allergen ; Asthma symptom adequately control shortacting β2 agonist ( e.g. , albuterol ) alone ; Have significant change regular asthma medication acute asthma exacerbation require corticosteroid rescue , hospitalization , emergency department visit least 4 week prior screen time first dose study drug Study Day 0 . Sexually active woman , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 21 day prior first dose study drug Study Day 0 , must agree continue use precaution Study Day 126 . Cessation birth control point discuss responsible physician . Sexually active men , unless surgically sterile , must likewise use effective method birth control ( condom ) must agree continue use precaution Study Day 126 ; Able complete followup period Study Day 126 , require protocol . Willing forego form experimental treatment study procedure study ; Able provide spirometric reading meet American Thoracic Society ( ATS ) standard ( ATS , 1995 ) . Receipt MEDI528 previous clinical study ; History allergy adverse reaction component MEDI528 formulation ; Lung disease allergic asthma ( e.g . chronic bronchitis ) ; Current use systemic inhaled immunosuppressive drug , include systemic inhaled corticosteroid ( topical corticosteroid permit ) , longacting β2 agonist , leukotriene antagonist , cromolyn sodium , nedocromil sodium , theophylline inhale systemic medication asthma shortacting β2 agonist , least 4 week prior study drug administration Study Day 0 . Current use βadrenergic antagonist ( e.g . propranolol ) . Any disease illness , asthma , may require use systemic corticosteroid study period . Acute illness evidence clinically significant active infection , fever ³ 38.0°C ( 100.5°F ) screening time study drug administration Study Day 0 ; Current allergyvaccination therapy ( i.e. , desensitization immunotherapy ) less 3 month stable maintenance dos prior baseline allergen inhalation challenge ; Receipt investigational drug therapy within 30 day biologic ( ) within 5 halflives agent prior first dose study drug Study Day 150 ; Receipt therapy leukocytedepleting agent unless recovery white cell count document screening ; Pregnancy ( sexually active female must negative serum pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Is nurse mother time study enrollment ; Evidence infection hepatitis B C virus , HIV1 HIV2 , active infection hepatitis A ; History significant systemic disease ( e.g. , cancer ; infection ; coronary artery disease cardiovascular disease ; hematological , renal , hepatic , endocrinologic , neurologic , rheumatologic , gastrointestinal disease ) ; History cancer nonmelanoma skin cancer cervical carcinomainsitu treat successfully curative therapy ; History primary immunodeficiency ; History pancreatitis ; History use tobacco product within 2 year baseline history smoking &gt; = 10 packyears ; Elective surgery plan time screen Study Day 126 ; Clinically significant abnormality ( asthma ) upon physical examination prior study drug administration Study Day 0 ; Clinically significant abnormality , determine investigator , 12lead ECG chest radiograph time screening ; At time screen , follow abnormality : aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , amylase &gt; 1.5 × upper limit normal ( ULN ) ; serum creatinine &gt; 1.3 × ULN ; abnormal laboratory value screen panel , opinion principal investigator ( PI ) , judge clinically significant ; Evidence systemic disease respiratory disease ( asthma ) , find upon physical examination history disease , opinion PI medical monitor , may compromise safety patient study confound analysis study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>